laitimes

Lilac Garden's "Lilac Doctor" and other self-media accounts have been banned shun as well-known wind investment stocks such as Tencent Hillhouse

author:China.com

China's network technology on August 10 (reporter Ye Xiaoyuan) yesterday, some netizens reported that "Lilac Garden", "Lilac Doctor" and other 5 Lilac Garden series of active Weibo accounts have been banned. China Net Technology searched on the Weibo platform to confirm that the Accounts of Lilac Garden Group, such as "Lilac Garden", "Lilac Doctor", "Lilac Life Research Institute", "Lilac Mother" and other Weibo accounts, have been restricted from speaking, and the platform prompt message is "Due to violations of relevant laws and regulations, the user is currently in a state of silence".

Lilac Garden's "Lilac Doctor" and other self-media accounts have been banned shun as well-known wind investment stocks such as Tencent Hillhouse
Lilac Garden's "Lilac Doctor" and other self-media accounts have been banned shun as well-known wind investment stocks such as Tencent Hillhouse
Lilac Garden's "Lilac Doctor" and other self-media accounts have been banned shun as well-known wind investment stocks such as Tencent Hillhouse

As of now, the number of followers of the "Doctor Lilac" Weibo account is about 5.98 million, and a total of 33,411 Weibo posts have been posted; The number of followers of the "Lilac Garden" Weibo account is about 2.17 million, and a total of 35,186 Weibo posts are published; The number of followers of the "Lilac Mother" Weibo account is about 110,000, and a total of 5,063 Microblogs are posted. The number of followers on other accounts is relatively small.

In addition, a search on the WeChat public platform found that some accounts such as "Lilac Garden", "Lilac Doctor", and "Lilac Mother" did not push content to users after August 9, and China Net Technology noted that these accounts had previously pushed about 3 pieces of content to users every day.

According to public information, Lilac Garden is a leading digital medical and health technology enterprise in China, which has served hundreds of millions of public users in the past 20 years and has 5.5 million professional users, including 2.1 million doctor users, accounting for 71% of the total number of doctors in China.

The reporter checked its official website and saw that in January 2010, the company obtained a DCM $2 million A round investment; In December 2012, it obtained Series B financing, led by Shunwei Fund and followed by DCM; In September 2014, it completed the C round of financing and obtained a strategic investment of US$70 million from Tencent; In April 2018, it completed the D round of financing, and was led by TrustTrust with an investment of 100 million US dollars, with a valuation of more than 1 billion US dollars; In December 2020, it completed a financing of US$500 million, led by TrustTrust, and followed by Tencent and Hillhouse Venture Capital.

Read on